story of the week
Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
Oncologist 2019 Aug 05;[EPub Ahead of Print], JM Segar, D Reed, A Stopeck, RB Livingston, P ChalasaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.